Yew Bio-Pharm Group, Inc. Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2021-09-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2021-09-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2021-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2021-09-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2021-09-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 29.05M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.04M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2021-09-30 | (m) | $29.05M | (m) | $1.04M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $39.30M | (m) | $4.09M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $34.02M | (m) | $5.38M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $27.31M | (m) | $2.57M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $25.08M | (m) | $765.89K | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | $343.93K | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | $623.63K | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | $27.88M | (m) | (m) | (m) | 0.00% | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | $-26.50K | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $43.82M | (m) | $114.39K | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $46.08M | (m) | $1.04M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | $37.60M | $1.07M | $718.60K | (m) | 0.00% | 2.84% | (m) | (m) |
| 2018-09-30 | (m) | $37.39M | (m) | $-4.18M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $34.91M | (m) | $-4.90M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $35.70M | (m) | $3.32M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | $40.54M | (m) | $3.32M | (m) | 0.00% | (m) | (m) | (m) |
| 2017-09-30 | (m) | $47.05M | $-119.88K | $9.62M | (m) | (m) | -0.25% | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $50.60M | $-1.38K | $1.27M | (m) | (m) | -0.00% | (m) | (m) |
| 2016-12-31 | $860.00 | $51.35M | $31.47K | $2.12M | (m) | 0.00% | 0.06% | (m) | (m) |
| 2016-09-30 | (m) | $56.61M | $412.31K | $4.82M | (m) | (m) | 0.73% | (m) | (m) |
| 2016-06-30 | (m) | $46.94M | $595.28K | $4.63M | (m) | (m) | 1.27% | (m) | (m) |
| 2016-03-31 | (m) | $35.55M | $756.10K | $5.22M | (m) | (m) | 2.13% | (m) | (m) |
| 2015-12-31 | $13.55K | $29.57M | $967.74K | $5.14M | (m) | 0.05% | 3.27% | (m) | (m) |
| 2015-09-30 | (m) | $14.20M | $961.52K | $4.43M | (m) | (m) | 6.77% | (m) | (m) |
| 2015-06-30 | (m) | $10.90M | (m) | $4.39M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $8.30M | (m) | $3.91M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $53.54K | $7.73M | $166.22K | $4.29M | (m) | 0.69% | 2.15% | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $7.67M | (m) | $4.42M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $7.71M | (m) | $4.33M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $23.13K | $7.44M | (m) | $3.90M | (m) | 0.31% | (m) | (m) | (m) |
| 2013-09-30 | (m) | $7.34M | (m) | $1.70M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $7.17M | (m) | $1.99M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $6.97M | (m) | $2.12M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $14.59K | $6.73M | $2.25M | $2.20M | (m) | 0.22% | 33.40% | (m) | (m) |
| 2012-09-30 | (m) | $6.38M | (m) | $4.55M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $6.21M | (m) | $4.39M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $16.05K | $5.96M | (m) | $4.05M | (m) | 0.27% | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.